Skip to main content
ECRAID-Base Training

Ecraid and GARDP to hold webinar on platform trials for new and neglected antimicrobials

GARDP, in collaboration with Ecraid, is hosting a REVIVE webinar about clinical trial platforms for new and neglected antimicrobials. Registration is open for the event which will take place on 20 September 2023.

The webinar will be moderated by Ecraid CEO Marc Bonten (Utrecht, the Netherlands), professor of molecular epidemiology of infectious diseases at University Medical Centre Utrecht. He will give the floor to two fellow infectious diseases experts: Jesús Rodríguez-Baño (Seville, Spain) and Julia Bielicki (Basel, Switzerland). 


Jesús is a professor of medicine at the University of Seville, as well as Head of the Infectious Diseases division at Hospital Universitario Virgen Macarena. He will discuss specificities of trials in complicated Urinary Tract Infections (cUTI) and new designs for such trials.

The main focus of this presentation will be POS-cUTI – a perpetual observational study led by Jesús himself. Its primary objective is setting up a pan-European infrastructure for rapidly implementing randomised controlled trials (RCTs) and other clinical studies related to the treatment of cUTI. The secondary objectives include descriptive analyses related to patient characteristics, complications, outcomes, and risk factors.

POS-cUTI is part of the EU-funded project ECRAID-Base.


The second part of the webinar is dedicated to a similar research project in neonatal sepsis – Severe Neonatal Infection Platform Africa (SNIP-AFRICA). The study will be presented by Julia Bielicki who is a senior consultant in paediatric infectious diseases at the University of Basel Children’s Hospital in Switzerland and a reader in paediatric infectious diseases at St George’s, University of London. 

Since the evidence base for neonatal sepsis management in low- and middle-income countries with high prevalence of resistant bacteria is limited, a research architecture is required to flexibly and efficiently accommodate a range of activities to address corresponding research questions. SNIP-AFRICA represents such an architecture to be implemented in the sub-Saharan African setting through leveraging the expertise, experience and on-going research of the diverse SNIP-AFRICA partnership. SNIP-AFRICA has been explicitly planned with extensions and adaptations in mind to facilitate integration of new interventions, in particular new or repurposed antibiotics, into its overall work plan.


To address the threats posed by drug resistance, the slow rate in the discovery and development of new treatments, and the abandonment of antimicrobial research, the Global Antibiotic Research & Development Partnership (GARDP) launched REVIVE in 2018. This education and outreach initiative aims to ensure that knowledge is retained, and the antimicrobial R&D community is supported to connect, share, and acquire information. With a network of world-class experts, REVIVE helps improve, accelerate, and streamline antimicrobial research and development by facilitating knowledge dissemination between clinical, industry and academic researchers at all stages of their careers.